Literature DB >> 35382123

Kidney involvement in systemic sclerosis: From pathogenesis to treatment.

Cosimo Bruni1,2, Giovanna Cuomo3, Francesca W Rossi4, Emanuela Praino5, Silvia Bellando-Randone1,2.   

Abstract

Among all possible systemic sclerosis internal organ complications, kidney involvement is frequently neglected or underestimated, except for the life-threatening scleroderma renal crisis. Fortunately, this severe clinical presentation is nowadays better controlled with available treatments, in particular angiotensin-converting enzyme inhibitors, and this has led to a reduction in its short- and longer-term mortality. Pathogenetic determinants are not well understood and many different other kidney involvements are possible in systemic sclerosis, including proteinuria, albuminuria, reduction of renal filtration, autoantibodies-related glomerulonephritis, and drug-related side effects. Different serological and radiological methods of evaluations are nowadays available, some representing promising diagnostic tool and prognostic outcome measure. Except for angiotensin-converting enzyme inhibitors in scleroderma renal crisis, no other treatment is currently recommended for treatment of kidney involvement in systemic sclerosis. For this reason, further studies are necessary to investigate its prognostic impact, in particular in combination with other systemic sclerosis-related internal organ manifestations. This review summarizes current available literature on kidney involvement in systemic sclerosis.
© The Author(s) 2018.

Entities:  

Keywords:  Kidney; Renal function; Scleroderma renal crisis; Systemic sclerosis

Year:  2018        PMID: 35382123      PMCID: PMC8892882          DOI: 10.1177/2397198318758607

Source DB:  PubMed          Journal:  J Scleroderma Relat Disord        ISSN: 2397-1983


  113 in total

Review 1.  The potential of endothelin antagonism as a therapeutic approach.

Authors:  Ariela Benigni; Norberto Perico; Giuseppe Remuzzi
Journal:  Expert Opin Investig Drugs       Date:  2004-11       Impact factor: 6.206

2.  Kidney disease other than renal crisis in patients with diffuse scleroderma.

Authors:  Virginia D Steen; Aijaz Syzd; John P Johnson; Arthur Greenberg; Thomas A Medsger
Journal:  J Rheumatol       Date:  2005-04       Impact factor: 4.666

3.  Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study.

Authors:  D C Trostle; C D Bedetti; V D Steen; M R Al-Sabbagh; B Zee; T A Medsger
Journal:  Arthritis Rheum       Date:  1988-03

Review 4.  Corticosteroids and the risk of scleroderma renal crisis: a systematic review.

Authors:  Gerald Trang; Russell Steele; Murray Baron; Marie Hudson
Journal:  Rheumatol Int       Date:  2010-12-04       Impact factor: 2.631

5.  Evaluation of Chronic Kidney Disease Epidemiology Collaboration equation to estimate glomerular filtration rate in scleroderma patients.

Authors:  Antonietta Gigante; Edoardo Rosato; Rita Massa; Carmelina Rossi; Biagio Barbano; Rosario Cianci; Ilenia Molinaro; Antonio Amoroso; Felice Salsano
Journal:  Rheumatology (Oxford)       Date:  2012-03-28       Impact factor: 7.580

6.  Immunohistological study endothelin-1 and endothelin-A and B receptors in two patients with scleroderma renal crisis.

Authors:  H Kobayashi; T Nishimaki; S Kaise; T Suzuki; K Watanabe; R Kasukawa; T Suzuki
Journal:  Clin Rheumatol       Date:  1999       Impact factor: 2.980

Review 7.  Renal complications and scleroderma renal crisis.

Authors:  C P Denton; G Lapadula; L Mouthon; U Müller-Ladner
Journal:  Rheumatology (Oxford)       Date:  2009-06       Impact factor: 7.580

8.  Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases.

Authors:  Y M Traub; A P Shapiro; G P Rodnan; T A Medsger; R H McDonald; V D Steen; T A Osial; S F Tolchin
Journal:  Medicine (Baltimore)       Date:  1983-11       Impact factor: 1.889

9.  Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli.

Authors:  T Nakamura; I Ebihara; M Fukui; Y Tomino; H Koide
Journal:  Diabetes       Date:  1995-08       Impact factor: 9.461

10.  Anti-annexin v antibodies: association with vascular involvement and disease outcome in patients with systemic sclerosis.

Authors:  Reem A Habeeb; Howaida E Mansour; Aya M Abdeldayem; Rania A Abo-Shady; Iman A Hassan; Nazek K Saafan; Dalia G Aly
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2010-04-28
View more
  2 in total

Review 1.  The Involvement of Smooth Muscle, Striated Muscle, and the Myocardium in Scleroderma: A Review.

Authors:  Ioana Bratoiu; Alexandra Maria Burlui; Anca Cardoneanu; Luana Andreea Macovei; Patricia Richter; Gabriela Rusu-Zota; Ciprian Rezus; Minerva Codruta Badescu; Andreea Szalontay; Elena Rezus
Journal:  Int J Mol Sci       Date:  2022-10-09       Impact factor: 6.208

Review 2.  Management of systemic sclerosis: the first five years.

Authors:  David Roofeh; Dinesh Khanna
Journal:  Curr Opin Rheumatol       Date:  2020-05       Impact factor: 4.941

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.